Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

83.69
Delayed Data
As of Sep 13
 +0.52 / +0.63%
Today’s Change
60.27
Today|||52-Week Range
99.73
+14.79%
Year-to-Date
What Makes Alnylam (ALNY) a New Buy Stock
Sep 13 / Zacks.com - Paid Partner Content
Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report?
Sep 05 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close83.17
Today’s open83.14
Day’s range83.04 - 85.69
Volume862,244
Average volume (3 months)805,000
Market cap$9.3B
Data as of 4:00pm ET, 09/13/2019

Growth & Valuation

Earnings growth (last year)-39.67%
Earnings growth (this year)-6.90%
Earnings growth (next 5 years)+163.00%
Revenue growth (last year)-16.69%
P/E ratioNM
Price/Sales97.91
Price/Book6.52

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...-0.68-1.02%
SAGESAGE Therapeutics In...-1.11-0.69%
GLPGGalapagos NV+1.09+0.68%
MYLMylan NV-0.55-2.47%
Data as of 4:15pm ET, 09/13/2019

Financials

Next reporting dateNovember 6, 2019
EPS forecast (this quarter)-$2.09
Annual revenue (last year)$74.9M
Annual profit (last year)-$761.5M
Net profit margin-1,016.58%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts